top of page

Guidance Documents

General Documents

Guidance for Industry - Contract Manufacturing Arrangements for Drugs: Quality Agreements

General Documents

Process Validation General Principles and Practices - Life Cycle Approach to Validation

Recombinant Proteins & Biologics

A-Mab- A Case Study in Risk Based Approach to Bio-process Development

Recombinant Proteins & Biologics

Points to consider in the Characterization of cell lines used to produce biologicals

Recombinant Proteins & Biologics

ICH Q10- Guidance for Industry Pharmaceutical Quality System

Recombinant Proteins & Biologics

ICH Q9- Guidance for Industry Quality Risk Management

Recombinant Proteins & Biologics

ICH Q8- Guidance for Industry on Pharmaceutical Development

Recombinant Proteins & Biologics

ICH Q5D - Guideline for Derivation and Characterization of Cell Substrates

Recombinant Proteins & Biologics

IND application

Recombinant Proteins & Biologics

Content and Format of IND for Drugs and Well Characterized Biologics

BioSimilars

Guidance for Industry - Scientific Considerations in Demonstrating Biosimilariy to a Reference Product

BioSimilars

Guidance for Industry - Demonstrating Biosimiliarity to a Reference Protein Product

Cell And Gene Therapy

Guidance for Industry - Potency tests for Cellular and Gene Therapy Products

Cell And Gene Therapy

Application of current statutory authorities to human somatic cell therapy products

Cell And Gene Therapy

Guidance for Human Somatic Cell Therapy and Gene Therapy

Cell And Gene Therapy

Guidance for Industry- Minimally manipulated unrelated allogeneic placental umbilical cord blood for hematopoetic reconstitution

Cell And Gene Therapy

Points to consider in collection, processing and testing of ex-vivo-activated mononuclear leukocytes

Cell And Gene Therapy

Proposed approach to regulation of cellular and tissue based products

Cell And Gene Therapy

A-VAX Application of Quality By Design to Vaccines - 2012
bottom of page